Investors
Financial Calendar
Annual General Meeting 2025
Semestrial Results 2025 non-audited
Full Year Results 2024
Q3 2024 Business and Financial Highlights
Half Year Results 2024
BioSenic was formed through a reverse merger between Bone Therapeutics and Medsenic. All financial information can be found below.
Shareholder Information
SHAREHOLDER STRUCTURE
SHARE INFORMATION
BioSenic's shares were listed on the regulated market of Euronext Brussels and Euronext Paris on February 6, 2015 under the symbol BIOS.
As of December 31, 2024, BioSenic has a total number of 231 335 822 outstanding shares.
Corporate Governance
IR Contact
BioSenic SA
Rue Léon Champagne, 3
1480 Saintes – Belgium
T.: +32 493 09 73 66
investorrelations@biosenic.com
BioSenic SA
Avenue Léon champagne, 3
1480 Saintes – Belgium
info@biosenic.com